Global Infertility Drugs Market Overview 2023-2028
Infertility drugs focus on the development, production, and distribution of medications specifically designed to address infertility issues in individuals. They are a crucial component of assisted reproductive technologies (ART) and play an essential role in assisting individuals or couples facing challenges in conceiving naturally. As they are formulated to aid in various aspects of fertility treatments, such as inducing ovulation, regulating hormone levels, and enhancing reproductive functions, the demand for infertility drugs is rising across the globe.
The global infertility drugs market size reached US$ 3.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.2 Billion by 2028, exhibiting a growth rate (CAGR) of 5.24% during 2023-2028.
Global Infertility Drugs Market Trends and Drivers:
At present, the increasing prevalence of infertility cases due to lifestyle changes, stress, delayed pregnancies, and environmental factors represents one of the major factors contributing to the growth of the market. Apart from this, the rising awareness about the availability of various treatment options around the world is propelling the growth of the market. Moreover, the increasing acceptance of assisted reproductive technologies (ART), along with the rising focus on patient-centric approaches, is bolstering the growth of the market. In line with this, the growing demand for personalized treatment solutions among individuals due to the inflating income level of individuals is positively influencing the market. Furthermore, the rising introduction of innovative products with enhanced efficacy and reduced side effects is strengthening the growth of the market.
Global Infertility Drugs Market 2023-2028 Analysis and Segmentation:
Top Key Players covered in this report are: Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex
The report segmented the market on the basis of region, drug class, route of administration, distribution channel and end user.
Breakup by Drug Class:
- Gonadotropin
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Biguanides
- Others
Breakup by Route of Administration:
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by End User:
- Male
- Female
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Key highlights of the report:
- Market Performance (2017-2022)
- Market Outlook (2023- 2028)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
